Cargando…

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer

BACKGROUND: Magnetic resonance imaging (MRI)-based risk calculators (MRI-RCs) individualise the likelihood of clinically significant prostate cancer (csPCa) and improve candidate selection for prostate biopsy beyond the Prostate Imaging Reporting and Data System (PI-RADS). OBJECTIVE: To compare the...

Descripción completa

Detalles Bibliográficos
Autores principales: Morote, Juan, Borque-Fernando, Ángel, Triquell, Marina, Campistol, Miriam, Servian, Pol, Abascal, José M., Planas, Jacques, Méndez, Olga, Esteban, Luis M., Trilla, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334241/
https://www.ncbi.nlm.nih.gov/pubmed/37441350
http://dx.doi.org/10.1016/j.euros.2023.03.013
_version_ 1785070819437707264
author Morote, Juan
Borque-Fernando, Ángel
Triquell, Marina
Campistol, Miriam
Servian, Pol
Abascal, José M.
Planas, Jacques
Méndez, Olga
Esteban, Luis M.
Trilla, Enrique
author_facet Morote, Juan
Borque-Fernando, Ángel
Triquell, Marina
Campistol, Miriam
Servian, Pol
Abascal, José M.
Planas, Jacques
Méndez, Olga
Esteban, Luis M.
Trilla, Enrique
author_sort Morote, Juan
collection PubMed
description BACKGROUND: Magnetic resonance imaging (MRI)-based risk calculators (MRI-RCs) individualise the likelihood of clinically significant prostate cancer (csPCa) and improve candidate selection for prostate biopsy beyond the Prostate Imaging Reporting and Data System (PI-RADS). OBJECTIVE: To compare the Barcelona (BCN) and Rotterdam (ROT) MRI-RCs in an entire population and according to the PI-RADS categories. DESIGN, SETTING, AND PARTICIPANTS: A prospective comparison of BCN- and ROT-RC in 946 men with suspected prostate cancer in whom systematic biopsy was performed, as well as target biopsies of PI-RADS ≥3 lesions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Saved biopsies and undetected csPCa (grade group ≥2) were determined. RESULTS AND LIMITATIONS: The csPCa detection was 40.8%. The median risks of csPCa from BCN- and ROT-RC were, respectively, 67.1% and 25% in men with csPCa, whereas 10.5% and 3% in those without csPCa (p < 0.001). The areas under the curve were 0.856 and 0.844, respectively (p = 0.116). BCN-RC showed a higher net benefit and clinical utility over ROT-RC. Using appropriate thresholds, respectively, 75% and 80% of biopsies were needed to identify 50% of csPCa detected in men with PI-RADS <3, whereas 35% and 21% of biopsies were saved, missing 10% of csPCa detected in men with PI-RADS 3. BCN-RC saved 15% of biopsies, missing 2% of csPCa in men with PI-RADS 4, whereas ROT-RC saved 10%, missing 6%. No RC saved biopsies without missing csPCa in men with PI-RADS 5. CONCLUSIONS: ROT-RC provided a lower and narrower range of csPCa probabilities than BCN-RC. BCN-RC showed a net benefit over ROT-RC in the entire population. However, BCN-RC was useful in men with PI-RADS 3 and 4, whereas ROT-RC was useful only in those with PI-RADS 3. No RC seemed to be helpful in men with negative MRI and PI-RADS 5. PATIENT SUMMARY: Barcelona risk calculator was more helpful than Rotterdam risk calculator to select candidates for prostate biopsy.
format Online
Article
Text
id pubmed-10334241
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103342412023-07-12 Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer Morote, Juan Borque-Fernando, Ángel Triquell, Marina Campistol, Miriam Servian, Pol Abascal, José M. Planas, Jacques Méndez, Olga Esteban, Luis M. Trilla, Enrique Eur Urol Open Sci Prostatic Disease BACKGROUND: Magnetic resonance imaging (MRI)-based risk calculators (MRI-RCs) individualise the likelihood of clinically significant prostate cancer (csPCa) and improve candidate selection for prostate biopsy beyond the Prostate Imaging Reporting and Data System (PI-RADS). OBJECTIVE: To compare the Barcelona (BCN) and Rotterdam (ROT) MRI-RCs in an entire population and according to the PI-RADS categories. DESIGN, SETTING, AND PARTICIPANTS: A prospective comparison of BCN- and ROT-RC in 946 men with suspected prostate cancer in whom systematic biopsy was performed, as well as target biopsies of PI-RADS ≥3 lesions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Saved biopsies and undetected csPCa (grade group ≥2) were determined. RESULTS AND LIMITATIONS: The csPCa detection was 40.8%. The median risks of csPCa from BCN- and ROT-RC were, respectively, 67.1% and 25% in men with csPCa, whereas 10.5% and 3% in those without csPCa (p < 0.001). The areas under the curve were 0.856 and 0.844, respectively (p = 0.116). BCN-RC showed a higher net benefit and clinical utility over ROT-RC. Using appropriate thresholds, respectively, 75% and 80% of biopsies were needed to identify 50% of csPCa detected in men with PI-RADS <3, whereas 35% and 21% of biopsies were saved, missing 10% of csPCa detected in men with PI-RADS 3. BCN-RC saved 15% of biopsies, missing 2% of csPCa in men with PI-RADS 4, whereas ROT-RC saved 10%, missing 6%. No RC saved biopsies without missing csPCa in men with PI-RADS 5. CONCLUSIONS: ROT-RC provided a lower and narrower range of csPCa probabilities than BCN-RC. BCN-RC showed a net benefit over ROT-RC in the entire population. However, BCN-RC was useful in men with PI-RADS 3 and 4, whereas ROT-RC was useful only in those with PI-RADS 3. No RC seemed to be helpful in men with negative MRI and PI-RADS 5. PATIENT SUMMARY: Barcelona risk calculator was more helpful than Rotterdam risk calculator to select candidates for prostate biopsy. Elsevier 2023-05-22 /pmc/articles/PMC10334241/ /pubmed/37441350 http://dx.doi.org/10.1016/j.euros.2023.03.013 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Prostatic Disease
Morote, Juan
Borque-Fernando, Ángel
Triquell, Marina
Campistol, Miriam
Servian, Pol
Abascal, José M.
Planas, Jacques
Méndez, Olga
Esteban, Luis M.
Trilla, Enrique
Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
title Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
title_full Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
title_fullStr Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
title_full_unstemmed Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
title_short Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
title_sort comparison of rotterdam and barcelona magnetic resonance imaging risk calculators for predicting clinically significant prostate cancer
topic Prostatic Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334241/
https://www.ncbi.nlm.nih.gov/pubmed/37441350
http://dx.doi.org/10.1016/j.euros.2023.03.013
work_keys_str_mv AT morotejuan comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT borquefernandoangel comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT triquellmarina comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT campistolmiriam comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT servianpol comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT abascaljosem comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT planasjacques comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT mendezolga comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT estebanluism comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer
AT trillaenrique comparisonofrotterdamandbarcelonamagneticresonanceimagingriskcalculatorsforpredictingclinicallysignificantprostatecancer